Effects of Rolipram on Spinal Cord Transection Injury in Rats
Abstract： Objective To investigate the possibility of rolipram for treatment of spinal cord injury (SCI) in rats. Methods 30 adult fe-male Sprague-Dawley rats were divided into sham-operation group (sham group, n=10), spinal cord injury group (SCI group, n=10) and ro-lipram treatment group (R group, n=10). The rats in SCI group and R group were modeled as spinal cord transection injury, and R group was administrated with rolipram subcutaneouly after SCI. They were assessed with Basso Beattie and Bresnahan (BBB) score 2, 4, 6, and 8 weeks after SCI, and the expressions of growth associated protein 43 (GAP-43) and glial fibrillary acidic protein (GFAP) were detected with immunohistochemistry 2 weeks after SCI. Results There were significant difference in the BBB scores between SCI and R groups 6 and 8 weeks after SCI (P<0.05). The expression of GAP-43 was more and GFAP was less in R group than in SCI group (P<0.05). Conclusion Ro-lipram can increase the expression of GAP-43 and inhibit the expression of GFAP, while improves the the motor function in rats after spinal cord transsection injury.
Keywords：spinal cord injuryroliprammotor functiongrowth associated protein 43glial fibrillary acidic proteinrats
Publication Date：2013-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 628-630 )